Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yu, Hui
NCT05255406: Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)	Recruiting	2	62	RoW	Furmonertinib (160mg), AST2818	Fudan University, Allist Pharmaceuticals, Inc.	Non-Small-Cell Lung Cancer	12/23	12/24
TRS00501001, NCT05395533: A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.	Recruiting	1	152	RoW	Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005	Zhejiang Teruisi Pharmaceutical Inc.	CD20-positive B-cell Non-Hodgkin Lymphoma	12/23	12/24
NCT05788835: DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial	Recruiting	N/A	220	RoW	DEB-TACE and HAIC, DEB-TACE	Xuhua Duan	HCC	06/24	06/26